Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;35(3):173-182.
doi: 10.5021/ad.22.216.

Basic Therapeutic Approach for Patients with Plaque Psoriasis: Korean Expert Consensus Using the Modified Delphi Method

Seong Jin Jo  1 , Yoo Sang Baek  2 , Tae-Gyun Kim  3 , Ki-Heon Jeong  4 , Jeong Eun Kim  5 , Yu Sung Choi  6 , Byungsoo Kim  7 , Eun-So Lee  8 , Yong Beom Choe  9 ; Korean Society for Psoriasis
Affiliations

Basic Therapeutic Approach for Patients with Plaque Psoriasis: Korean Expert Consensus Using the Modified Delphi Method

Seong Jin Jo et al. Ann Dermatol. 2023 Jun.

Abstract

Background: Currently, there is no consensus on the treatment of psoriasis in Korean patients.

Objective: This study aimed to establish a consensus on the basic therapeutic principles for Korean patients with plaque psoriasis.

Methods: Using the modified Delphi method, a steering committee proposed 53 statements for the first Delphi round, which covered five subjects: (1) the goal of treatment and evaluation of disease severity, (2) topical therapy, (3) phototherapy, (4) conventional systemic therapy, and (5) biologic therapy. The panel of dermatologists scored the level of agreement for each statement on a ten-point scale with scores ranging from 1 (strongly disagree) to 10 (strongly agree). After discussing the results of the first round, the committee reformulated 41 statements. Finally, consensus was defined as more than 70% of the second round scores being ≥7.

Results: The panel participants strongly agreed that the ideal treatment goals for Korean patients with plaque psoriasis should include complete skin clearance and high dermatological quality of life. A strong consensus was also reached on the use of topical agents for psoriasis of any severity, the consideration of phototherapy before biologics therapy, the conventional systemic agents for moderate-to-severe psoriasis, and the recommendation of biologic for retractable psoriasis to conventional systemic therapy and phototherapy.

Conclusion: This modified Delphi panel established an expert consensus on the therapeutic approach for Korean patients with plaque psoriasis. This consensus may improve the treatment outcomes for psoriasis in Korea.

Keywords: Consensus; Korea; Psoriasis; Therapeutics; Treatment.

PubMed Disclaimer

Conflict of interest statement

Dr. Seong Jin Jo reported grants from AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion Healthcare, Daewoong, Green Cross Laboratories, Janssen, LEO Pharma, Novartis, and UCB; consulting fees from Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Kolon Pharma, LEO Pharma, and Novartis; honoraria from AbbVie, Boehringer Ingelheim, Janssen, Kolon Pharma, LEO Pharma, Eli Lilly, and Novartis. Dr. Yoo Sang Baek reported grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Novartis, and Kolon Pharma; honoraria from Novartis. Dr. Tae-Gyun Kim has no conflict of interest to declare. Dr. Ki-Heon Jeong reported grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, and Novartis; honoraria from AbbVie, Eli Lilly, Janssen, LEO Pharma, and Novartis. Dr. Jeong Eun Kim reported grants from Novartis; honoraria from Novartis, Janssen, AbbVie, and Kolon Pharma. Dr. Yu Sung Choi reported grants from Eli Lilly; honoraria from AbbVie, Janssen, LEO Pharma, Novartis, and Kolon Pharma. Dr. Byungsoo Kim reported grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Novartis, Kolon Pharma, Janssen, Sanofi, Boehringer Ingelheim, Celltrion Healthcare, Green Cross Laboratories, Samsung Bioepis, and UCB; honoraria from AbbVie, Eli Lilly, Novartis, Kolon Pharma, and Janssen. Dr. Eun-So Lee reported grants from AbbVie, Janssen, Samsung Bioepis, and Eli Lilly; honoraria from AbbVie, Galderma Korea, Janssen, Eli Lilly, and Novartis. Dr. Yong Beom Choe reported grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Novartis, and Kolon Pharma; honoraria from Novartis, Eli Lilly, Janssen, and AbbVie.

References

    1. Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179:173–181. - PubMed
    1. Han B, Jeong KH, Kim TG, Kim KJ, Kim DH, Kim BS, et al. The economic burden of psoriasis in Korea. Korean J Dermatol. 2021;59:321–331.
    1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509. - PubMed
    1. Patrick MT, Li Q, Wasikowski R, Mehta N, Gudjonsson JE, Elder JT, et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun. 2022;13:6565. - PMC - PubMed
    1. Cho SI, Kim YE, Jo SJ. Association of metabolic comorbidities with pediatric psoriasis: a systematic review and meta-analysis. Ann Dermatol. 2021;33:203–213. - PMC - PubMed